Biodexa Pharmaceuticals plc reports news on a clinical-stage biopharmaceutical pipeline focused on gastrointestinal cancers, rare diseases and other unmet medical needs. The company’s programs include eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, MTX240, a molecular glue candidate for gastrointestinal stromal tumors, and tolimidone for type 1 diabetes.
Recurring developments cover clinical development, regulatory and trial authorizations, manufacturing and access partnerships, licensing, annual results, financing activity, ADR program matters and patient-advocacy initiatives. Biodexa’s American depositary shares trade under BDRX, while company updates may also describe ordinary-share and ADR mechanics for the U.K. issuer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Biodexa Pharmaceuticals PLC has announced the exercise of Pre-Funded Warrants leading to the issuance of 6,275,465 new ordinary shares at a price of US$0.0004 per warrant, effectively generating gross proceeds of US$502.04. This transaction relates to 1,255,093 Pre-Funded Warrants exercised on April 18, 2023. The new shares will be admitted for trading on the AIM of the London Stock Exchange around April 25, 2023. Post-admission, the company’s total ordinary shares will be 94,629,412, with the new shares ranking pari passu with existing ones. This adjustment serves as a numerator for shareholders calculating their interests under the FCA's regulations.